FDA-approved drug kills cancer cells in lab by disrupting cellular recycling
Researchers from VCU Massey Comprehensive Cancer Center recently demonstrated that the inhibition of glucosylceramide synthase (GCS) can cause death in cancer cells that is independent of changes in pro-death ceramide levels. The findings, which were recently published in Cell Death Discovery, showed that using eliglustat, an FDA-approved drug, induced cell death in several cancer cell lines.…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
